# US 2019/0315808 A1 · Adenoviral Polypeptide IX Increases Adenoviral Gene Therapy Vector Productivity and Infectivity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315808 A1
- Document ID: US20190315808A1
- Status: Published application
- Kind: A1
- Application number: 16/423,215
- Filed: 2019-05-28
- Published: 2019-10-17
- Earliest claimed: 2019-05-07
- Assignees: Kuopio Center for Gene and Cell Therapy Oy
- Applicants: Kuopio Center for Gene and Cell Therapy Oy
- Inventors: Vesa TURKKI; Saana LEPOLA; Hanna LESCH
- Web page: https://patentgrep.com/patent/US20190315808A1

## CPC

- C07K 14/005: from viruses
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61K 48/0091: {Purification or manufacturing processes for gene therapy compositions}
- C12N 5/0603: {Embryonic cells (production of embryos, nuclear transfer A01K67/027); Embryoid bodies}
- C12N 7/025: {Packaging cell lines, e.g. transcomplementing cell lines, for production of virus}
- C12N 15/86: Viral vectors
- C12N 2510/00: Genetically modified cells
- C12N 2710/00052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2710/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/10023: Virus like particles [VLP]
- C12N 2710/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/10043: viral genome or elements thereof as genetic vector
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/10352: relating to complementing cells and packaging systems for producing virus or viral particles
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Producing adenovirus gene therapy vector in producer cells that express or over-express adenoviral polypeptide IX enables one to produce pIX-deleted adenovirus in suspension cell culture. Using producer cells that express or over-express adenoviral polypeptide IX also increases the yield of adenovirus vector, regardless of whether that adenovirus is pIX-deleted. Using producer cells that express or over-express adenoviral polypeptide IX also improves the resulting vector's transduction kinetics, reducing the number of pfu/target cell required to achieve a given level of transduction/infection, shortening the time the vector requires to transduce or infect a target cell, and shortening the time an infected target cell produces progeny virus.

## Claims

### Claim 1

An adenoviral gene therapy vector comprising adenovirus protein IX and an expressible transgene, said adenoviral gene therapy vector produced in a human cell which expresses adenovirus protein IX even when not infected or transduced by an adenovirus.

### Claim 2 (depends on 1)

The adenoviral gene therapy vector of claim 1, wherein the adenoviral gene therapy vector comprises about twelve (12) adenovirus protein IX molecules per adenoviral gene therapy vector particle.

### Claim 3 (depends on 1)

The adenoviral gene therapy vector of claim 1, wherein the human cell expresses adenovirus protein IX in a greater than stoichiometric amount.

### Claim 4 (depends on 1)

The adenoviral gene therapy vector of claim 1, wherein the human cell produces a greater amount of adenovirus protein IX than does a similar human cell that has been infected with wild-type adenovirus at a Multiplicity of Infection of 1.

### Claim 5 (depends on 1)

The adenoviral gene therapy vector of claim 1, wherein the adenoviral gene therapy vector is conditionally replicative.

### Claim 6 (depends on 1)

The adenoviral gene therapy vector of claim 1, wherein the expressible transgene is, in a human patient, therapeutic.

### Claim 7 (depends on 1)

The adenoviral gene therapy vector of claim 1, wherein the adenoviral gene therapy vector has a genome comprising a nucleic acid sequence that is idiosyncratic to adenovirus.

### Claim 8 (depends on 1)

The adenoviral gene therapy vector of claim 1, wherein the adenoviral gene therapy vector has a genome which does not contain an expressed pix gene.

### Claim 9 (depends on 1)

The adenoviral gene therapy vector of claim 1, wherein the adenoviral gene therapy vector has a genome comprising an adenoviral packaging signal which does not have a cre/lox site flanking it.

### Claim 10 (depends on 1)

The adenoviral gene therapy vector of claim 1, wherein the vector is at least twice as infective, when measured 48 hours post-transformation, as the same vector produced in a similar producer cell which does not express adenovirus protein IX.

### Claim 11 (depends on 1)

The adenoviral gene therapy vector of claim 1, wherein the vector shows a cytopathic effect on target cells at least about 25% faster than does the same adenoviral gene therapy vector produced in a similar producer cell which does not express adenovirus protein IX.

### Claim 12 (depends on 1)

A mixture of the adenoviral gene therapy vector of claim 1 and non-infective adenoviral virus-like particles (VLPs), wherein the ratio of gene therapy vector to VLPs is greater than 1:100, where infectivity is measured by a plaque-forming assay.

### Claim 13 (depends on 1)

The adenoviral gene therapy vector of claim 1, where the vector has a genome larger than 35 kb.

### Claim 14 (depends on 1)

The adenoviral gene therapy vector of claim 1, wherein the human cell is grown in a non-adherent, suspension culture when producing the adenoviral gene therapy vector.

### Claim 15 (depends on 1)

The adenoviral gene therapy vector of claim 1, where the producer cell comprises a plasmid having an expressed ply gene.

### Claim 16

An adenoviral gene therapy vector having a genome comprising an adenoviral packaging signal which does not have a cre/lox site flanking it, produced in a producer cell which expresses adenovirus protein IX even when not infected or transduced by an adenovirus.

### Claim 17 (depends on 16)

The adenoviral gene therapy vector of claim 16, wherein the adenoviral gene therapy vector comprises about twelve (12) adenovirus protein IX molecules per adenoviral gene therapy vector particle.

### Claim 18 (depends on 16)

The adenoviral gene therapy vector of claim 16, wherein the human cell expresses adenovirus protein IX in a greater than stoichiometric amount.

### Claim 19 (depends on 16)

The adenoviral gene therapy vector of claim 16, wherein the human cell produces a greater amount of adenovirus protein IX than does a similar human cell that has been infected with wild-type adenovirus at a Multiplicity of Infection of 1.

### Claim 20 (depends on 16)

The adenoviral gene therapy vector of claim 16, wherein the adenoviral gene therapy vector is conditionally replicative.

### Claim 21 (depends on 16)

The adenoviral gene therapy vector of claim 16, wherein the expressible transgene is, in a human patient, therapeutic.

### Claim 22 (depends on 16)

The adenoviral gene therapy vector of claim 16, wherein the adenoviral gene therapy vector has a genome comprising a nucleic acid sequence that is idiosyncratic to adenovirus.

### Claim 23 (depends on 16)

The adenoviral gene therapy vector of claim 16, wherein the adenoviral gene therapy vector has a genome which does not contain an expressed pix gene.

### Claim 24 (depends on 16)

The adenoviral gene therapy vector of claim 16, wherein the adenoviral gene therapy vector has a genome comprising an adenoviral packaging signal which does not have a cre/lox site flanking it.

### Claim 25 (depends on 16)

The adenoviral gene therapy vector of claim 16, wherein the vector is at least twice as infective, when measured 48 hours post-transformation, as the same vector produced in a similar producer cell which does not express adenovirus protein IX.

### Claim 26 (depends on 16)

The adenoviral gene therapy vector of claim 16, wherein the vector shows a cytopathic effect on target cells at least about 25% faster than does the same adenoviral gene therapy vector produced in a similar producer cell which does not express adenovirus protein IX.

### Claim 27 (depends on 16)

A mixture of the adenoviral gene therapy vector of claim 16 and non-infective adenoviral virus-like particles (VLPs), wherein the ratio of gene therapy vector to VLPs is greater than 1:100, where infectivity is measured by a plaque-forming assay.

### Claim 28 (depends on 16)

The adenoviral gene therapy vector of claim 16, where the vector has a genome larger than 35 kb.

### Claim 29 (depends on 16)

The adenoviral gene therapy vector of claim 16, wherein the human cell is grown in a non-adherent, suspension culture when producing the adenoviral gene therapy vector.

### Claim 30 (depends on 16)

The adenoviral gene therapy vector of claim 16, where the producer cell comprises a plasmid having an expressed ply gene.

### Claim 31

An adenoviral gene therapy vector comprising adenovirus protein IX and an expressible transgene, the adenoviral gene therapy vector having a genome which does not have an expressed ply gene.

### Claim 32 (depends on 31)

The adenoviral gene therapy vector of claim 31, wherein the adenoviral gene therapy vector comprises about twelve (12) adenovirus protein IX molecules per adenoviral gene therapy vector particle.

### Claim 33 (depends on 31)

The adenoviral gene therapy vector of claim 31, wherein the adenoviral gene therapy vector is produced in a human cell which expresses adenovirus protein IX even when not infected or transduced by an adenovirus.

### Claim 34 (depends on 33)

The adenoviral gene therapy vector of claim 33, wherein the human cell expresses adenovirus protein IX in a greater than stoichiometric amount.

### Claim 35 (depends on 33)

The adenoviral gene therapy vector of claim 33, wherein the human cell produces a greater amount of adenovirus protein IX than does a similar human cell that has been infected with wild-type adenovirus at a Multiplicity of Infection of 1.

### Claim 36 (depends on 31)

The adenoviral gene therapy vector of claim 31, wherein the adenoviral gene therapy vector is conditionally replicative.

### Claim 37 (depends on 31)

The adenoviral gene therapy vector of claim 31, wherein the expressible transgene is, in a human patient, therapeutic.

### Claim 38 (depends on 31)

The adenoviral gene therapy vector of claim 31, wherein the adenoviral gene therapy vector has a genome comprising a nucleic acid sequence that is idiosyncratic to adenovirus.

### Claim 39 (depends on 1)

The adenoviral gene therapy vector of claim 1, wherein the adenoviral gene therapy vector has a genome comprising an adenoviral packaging signal which does not have a cre/lox site flanking it.

### Claim 40 (depends on 31)

The adenoviral gene therapy vector of claim 31, wherein the vector is at least twice as infective, when measured 48 hours post-transformation, as the same vector produced in a similar producer cell which does not express adenovirus protein IX.

### Claim 41 (depends on 31)

The adenoviral gene therapy vector of claim 31, wherein the vector shows a cytopathic effect on target cells at least about 25% faster than does the same adenoviral gene therapy vector produced in a similar producer cell which does not express adenovirus protein IX.

### Claim 42 (depends on 1)

A mixture of the adenoviral gene therapy vector of claim 1 and non-infective adenoviral virus-like particles (VLPs), wherein the ratio of gene therapy vector to VLPs is greater than 1:100, where infectivity is measured by a plaque-forming assay.

### Claim 43 (depends on 31)

The adenoviral gene therapy vector of claim 31, where the vector has a genome larger than 35 kb.

### Claim 44 (depends on 33)

The adenoviral gene therapy vector of claim 33, wherein the human cell is grown in a non-adherent, suspension culture when producing the adenoviral gene therapy vector.

### Claim 45 (depends on 33)

The adenoviral gene therapy vector of claim 33, where the producer cell comprises a plasmid having an expressed pix gene.

### Claim 46

A cell which expresses adenovirus protein IX even when not infected or transduced by an adenovirus, and which expresses adenovirus protein IX in a greater amount than does a similar cell that has been infected with wild-type adenovirus at a Multiplicity of Infection of not more than 1.

### Claim 47 (depends on 46)

The cell of claim 46, where the cell is human.

### Claim 48 (depends on 47)

The cell of claim 47, where the cell is a human embryonic kidney cell.

### Claim 49 (depends on 46)

The cell of claim 46, wherein the cell further produces adenoviral gene therapy vector having a transgene.

### Claim 50 (depends on 49)

The cell of claim 49, wherein the adenoviral gene therapy vector comprises about twelve (12) adenovirus protein IX molecules per adenoviral gene therapy vector particle.

### Claim 51 (depends on 49)

The cell of claim 49, wherein the cell expresses adenovirus protein IX in a greater than stoichiometric amount.

### Claim 52 (depends on 49)

The cell of claim 49, wherein the adenoviral gene therapy vector is conditionally replicative.

### Claim 53 (depends on 49)

The cell of claim 49, wherein the expressible transgene is, in a human patient, therapeutic.

### Claim 54 (depends on 49)

The cell of claim 49, wherein the adenoviral gene therapy vector has a genome comprising a nucleic acid sequence that is idiosyncratic to adenovirus.

### Claim 55 (depends on 49)

The cell of claim 49, wherein the adenoviral gene therapy vector has a genome which does not contain an expressed pix gene.

### Claim 56 (depends on 49)

The cell of claim 49, wherein the adenoviral gene therapy vector has a genome comprising an adenoviral packaging signal which does not have a cre/lox site flanking it.

### Claim 57 (depends on 49)

The cell of claim 49, wherein the adenoviral gene therapy vector is at least twice as infective, when measured 48 hours post-transformation, as the same vector produced in a similar producer cell which does not express adenovirus protein IX.

### Claim 58 (depends on 49)

The cell of claim 49, wherein the adenoviral gene therapy vector shows a cytopathic effect on target cells at least about 25% faster than does the same adenoviral gene therapy vector produced in a similar producer cell which does not express adenovirus protein IX.

### Claim 59 (depends on 49)

The cell of claim 49, wherein the cell further produces non-infective adenoviral virus-like particles (VLPs), and wherein the ratio of gene therapy vector to VLPs is greater than 1:100, where infectivity is measured by a plaque-forming assay.

### Claim 60 (depends on 49)

The cell of claim 49, where the vector has a genome larger than 35 kb.

### Claim 61 (depends on 46)

The cell of claim 46, grown in a non-adherent, suspension culture.

### Claim 62 (depends on 49)

The cell of claim 49, grown in a non-adherent, suspension culture when producing the adenoviral gene therapy vector.

### Claim 63 (depends on 46)

The cell of claim 46, wherein the cell comprises a plasmid having an expressed pix gene.

### Claim 64 (depends on 49)

The cell of claim 49, wherein the cell produces more than about 3231 virus genomes per cell.

### Claim 65 (depends on 49)

The cell of claim 49, wherein the cell produces at least about 4.7×109 viral genomes per milliliter of culture media.

### Claim 66

A suspension-cultured cell that expresses adenovirus protein IX even when not infected or transduced by an adenovirus.

### Claim 67 (depends on 66)

The suspension-cultured cell of claim 66, wherein the cell expresses adenovirus protein IX in a greater amount than does a similar cell that has been infected with wild-type adenovirus at a Multiplicity of Infection of not more than 1.

### Claim 68 (depends on 66)

The suspension-cultured cell of claim 66, where the cell is human.

### Claim 69 (depends on 69)

The suspension-cultured cell of claim 69, where the cell is a human embryonic kidney cell.

### Claim 70 (depends on 66)

The suspension-cultured cell of claim 66, wherein the suspension-cultured cell further produces adenoviral gene therapy vector having a transgene.

### Claim 71 (depends on 70)

The suspension-cultured cell of claim 70, wherein the adenoviral gene therapy vector comprises about twelve (12) adenovirus protein IX molecules per adenoviral gene therapy vector particle.

### Claim 72 (depends on 70)

The suspension-cultured cell of claim 70, wherein the cell expresses adenovirus protein IX in a greater than stoichiometric amount.

### Claim 73 (depends on 49)

The suspension-cultured cell of claim 49, wherein the adenoviral gene therapy vector is conditionally replicative.

### Claim 74 (depends on 70)

The suspension-cultured cell of claim 70, wherein the expressible transgene is, in a human patient, therapeutic.

### Claim 75 (depends on 70)

The suspension-cultured cell of claim 70, wherein the adenoviral gene therapy vector has a genome comprising a nucleic acid sequence that is idiosyncratic to adenovirus.

### Claim 76 (depends on 70)

The suspension-cultured cell of claim 70, wherein the adenoviral gene therapy vector has a genome which does not contain an expressed pix gene.

### Claim 77 (depends on 70)

The suspension-cultured cell of claim 70, wherein the adenoviral gene therapy vector has a genome comprising an adenoviral packaging signal which does not have a cre/lox site flanking it.

### Claim 78 (depends on 70)

The suspension-cultured cell of claim 70, wherein the adenoviral gene therapy vector is at least twice as infective, when measured 48 hours post-transformation, as the same vector produced in a similar producer cell which does not express adenovirus protein IX.

### Claim 79 (depends on 70)

The suspension-cultured cell of claim 70, wherein the adenoviral gene therapy vector shows a cytopathic effect on target cells at least about 25% faster than does the same adenoviral gene therapy vector produced in a similar producer cell which does not express adenovirus protein IX.

### Claim 80 (depends on 70)

The suspension-cultured cell of claim 70, wherein the suspension-cultured cell further produces non-infective adenoviral virus-like particles (VLPs), and wherein the ratio of gene therapy vector to VLPs is greater than 1:100, where infectivity is measured by a plaque-forming assay.

### Claim 81 (depends on 70)

The suspension-cultured cell of claim 70, where the adenoviral gene therapy vector has a genome larger than 35 kb.

### Claim 82 (depends on 70)

The suspension-cultured cell of claim 70, wherein the suspension-cultured cell comprises a plasmid having an expressed pix gene.

### Claim 83 (depends on 70)

The cell of claim 70, wherein the cell produces at least about 4.7×109 viral genomes per milliliter of culture media.

### Claim 84

A method for manufacturing a pix-deleted adenoviral gene therapy vector in suspension cell culture, comprising: culturing in suspension cell culture a producer cell which expresses adenoviral protein IX even if not infected or transduced by adenovirus, transforming the cell with a pix-deleted adenoviral gene therapy vector genome, culturing the cell in suspension while the cell produces a pix-deleted adenoviral gene therapy vector, and then harvesting adenoviral gene therapy vector comprising adenovirus protein IX and a therapeutic transgene.

### Claim 85 (depends on 1)

The method of claim 1, wherein the cell produces at least about 4.7×109 viral genomes per milliliter.

### Claim 86

An adenoviral gene therapy vector manufacturing process comprising obtaining human cells, transducing or transfecting those cells with expressible nucleic acid coding for adenovirus and with expressible nucleic acid coding for adenovirus protein IX, and with nucleic acid coding for a transgene, and then culturing the cells in suspension culture to produce adenoviral gene therapy vector comprising adenovirus protein IX and the transgene, and then harvesting the adenoviral gene therapy vector comprising adenovirus protein IX and the transgene.

### Claim 87

A virus manufacturing process comprising obtaining human producer cells that express adenovirus protein IX, and then transducing or transfecting those cells with nucleic acid coding for an adenoviral gene therapy vector, and then culturing the cells in suspension culture to produce adenovirus protein IX and the adenoviral gene therapy vector, and then harvesting adenoviral gene therapy vector comprising adenovirus protein IX.

### Claim 88 (depends on 87)

The manufacturing process of claim 87, wherein the nucleic acid coding for an adenoviral gene therapy vector is pix-negative

### Claim 89

A manufacturing method for increasing the yield of adenoviral gene therapy vector, comprising manufacturing an adenoviral gene therapy vector in a producer cell that expresses adenovirus protein IX even when not infected or transduced by adenovirus and then harvesting adenoviral gene therapy vector, whereby the ratio of infective adenoviral gene therapy vector produced to viral genomes produced is at least about 20% greater than the ratio obtained when producing the same adenoviral gene therapy vector in a producer cell that does not expresses adenoviral Protein IX when not infected or transduced by adenovirus.

### Claim 90 (depends on 1)

A human therapeutic method comprising administering to a human the adenoviral gene therapy vector of claim 1.
